Regeneron antibody cuts risk of COVID-19 death in UK study

Bio Pharma Dive

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients

Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody

Bio Pharma Dive

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FDA clears Lilly's COVID-19 antibody cocktail for emergency use

Bio Pharma Dive

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact

Who would get Regeneron's COVID-19 antibody treatment?

Bio Pharma Dive

Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

US stops rollout of Lilly's first COVID-19 antibody over variant concerns

Bio Pharma Dive

Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

F.D.A. Authorizes Another Antibody Treatment

NY Times

internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.

J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies

Bio Pharma Dive

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors

Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push

Bio Pharma Dive

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

Bio Pharma Dive

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.

Regeneron enlists Roche to boost production of COVID-19 antibody drug

Bio Pharma Dive

Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own

Boehringer goes after antibody cancer drugs in latest acquisition

Bio Pharma Dive

billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy For about $1.4

Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope

Pharma Phorum

Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on.

Regeneron joins Lilly in proving lower-dose antibody drugs can thwart COVID-19

Bio Pharma Dive

The findings could help boost the supply and reach of Regeneron's COVID-19 antibody drug, which, despite limited use, is now backed by convincing data showing it can prevent hospitalization

Vir breaks through with study success for COVID-19 antibody

Bio Pharma Dive

A data monitoring board said a study testing Vir's drug should be stopped early because of an overwhelming benefit from treatment

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Bio Pharma Dive

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020

Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug

Bio Pharma Dive

The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use

U.S. Buys 100,000 Doses of an Eli Lilly Antibody Treatment

NY Times

internal-essential Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Antibodies Eli Lilly and CompanyThe government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.

Latest Monoclonal Antibody Treatment Approved for High-Risk Patients

NY Times

GlaxoSmithKline PLC Food and Drug Administration Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV The drug, from GlaxoSmithKline and Vir, aims to keep Covid patients out of the hospital.

Regeneron’s COVID-19 Monoclonal Antibody Treatment First to Reduce Risk of Death in Hospitalized Patients

XTalks

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. Regeneron has enlisted the help of Roche to help manufacture the antibody drug.

In multiple myeloma, cell therapies lead but antibody drugs could follow fast

Bio Pharma Dive

But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.

Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study

Bio Pharma Dive

The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19

Lilly allies with Vir, GSK as coronavirus variants raise worries about antibody drugs

Bio Pharma Dive

The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers

AZ’s COVID jab tackles delta variant, but antibody fails clinical trial

Pharma Phorum

Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo.

Biogen abandons tau antibody for Alzheimer’s after phase 2 miss

Pharma Phorum

Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The post Biogen abandons tau antibody for Alzheimer’s after phase 2 miss appeared first on.

Monoclonal Antibody Proves Worth in Asthma Study

BioSpace

Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma

Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test

BioTech 365

Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo.–(BUSINESS

EU starts rolling review of GSK’s antibody for COVID-19

Pharma Phorum

The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU. . EMA_News starts evaluating the monoclonal antibody sotrovimab.

Provention faces delay in FDA review of diabetes prevention antibody

Pharma Phorum

An advisory committee meeting to discuss the antibody is however still due to go ahead as scheduled on 27 May, according to Provention, and the FDA’s priority review is still ongoing. The post Provention faces delay in FDA review of diabetes prevention antibody appeared first on.

EMA starts review of GSK/Vir COVID-19 antibody

Pharma Phorum

The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. . The post EMA starts review of GSK/Vir COVID-19 antibody appeared first on.

LSBio Acquires Absolute Antibody Ltd.

BioTech 365

LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd.

AZ deploys mobile sites to test COVID-19 antibody AZD7442

Pharma Phorum

AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims to narrow the gap with the help of decentralised clinical trial specialist Care Access Research. The post AZ deploys mobile sites to test COVID-19 antibody AZD7442 appeared first on.

Can new Regeneron, Lilly data move the needle for COVID-19 antibody drugs?

Bio Pharma Dive

The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high

NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial

Pharma Phorum

According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19.

Lilly asks FDA to revoke clearance of first COVID-19 antibody drug

Bio Pharma Dive

The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug

Companies Press Ahead with COVID-19 Antibody Therapies

BioSpace

Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease

IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies

BioTech 365

Eli Lilly’s Dual Antibody Bamlanivimab and Etesevimab Treatment Lowers Risk of COVID-19 Hospitalizations and Deaths

XTalks

Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent.

Antibodies, Immunity, and COVID-19

JAMA Internal Medicine

Widespread availability of commercial assays that detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has enabled researchers to examine naturally acquired immunity to coronavirus disease 2019 (COVID-19) at the population level. The study uses national data to expand on an earlier US Centers for Disease Control and Prevention study of seroprevalence of antibodies to SARS-CoV-2 in 10 US sites

What to Know of Covid-19 Antibody Drugs: Cost, Availability and More

NY Times

Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Eli Lilly and Company Regeneron Pharmaceuticals Inc Food and Drug Administration Antibodies your-feed-healthcareHere’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.

Vir, GSK win US nod for another COVID-19 antibody drug as rival falters

Bio Pharma Dive

Vir's sotrovimab arrives months after similar treatments from Eli Lilly and Regeneron. But the drug could still play a role due to its apparent potency against variants that have challenged Lilly's drugs

Lilly, with new data, seeks emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination